Pembrolizumab/Olaparib Combo May Yield Better Responses in mCRPC Regardless of HRR Status

Article

Patients with metastatic castration-resistant prostate cancer experienced an improvement in prostate-specific antigen following treatment with pembrolizumab and olaparib.

Treatment with pembrolizumab (Keytruda) and olaparib (Lynparza) could help to improve prostate-specific antigen (PSA) response rates in patients with metastatic castration-resistant prostate cancer (mCRPC) regardless of homologous recombination repair (HRR) mutation status, according to findings from the KEYNOTE-365 trial (NCT02861573) that were presented at the 2021 European Society for Medical Oncology Congress.

The investigators also found high concordance between the Guardant Health (360 or Omni) assays and FoundationOne CDx for the detection of BRCA and HRR mutations.

The study included patients from cohort A of the KEYNOTE-365 trial, which investigated pembrolizumab at 200 mg IV every 3 weeks plus olaparib at 400 or 300 mg twice daily in patients with molecularly unselected, docetaxel-pretreated mCRPC.

For the current study, the investigators sought to “evaluate the prevalence of BRCA1 and/or BRCA2 mutations and other HRR mutations and their association with antitumor activity with pembrolizumab plus olaparib,” according to the study’s poster.

Primary end points included PSA response rate (50% or greater reduction from baseline), and objective response rate (ORR) per RECIST v1.1 by central review. Secondary end points included radiographic progression-free survival and overall survival.

The investigators assessed mutations in ctDNA using Guardant360 or GuardantOMNI assays. Guardant360 was used for detecting BRCA1, BRCA2, and ATM mutations. FoundationOneCDx was used to assess mutations in DNA isolated from formalin-fixed, paraffin-embedded tumor samples.

BRCA mutations were detected in 3 of 98 patients using Guardant360 or GuardantOMNI, and in 4 of 41 patients using FoundationOneCDx. HRR mutations were found in 14 of 59 patients using Guardant360 or GuardantOMNI and 12 of 41 patients using FoundationOneCDx.

PSA response was 50% in patients with a BRCA mutation (2 of 4 patients; 95% CI, 6.8%-93.2%) and 14% in patients without a BRCA mutation (13 of 95 patients; 95% CI, 7.5%-22.3%). In patients with an HRR mutation, PSA response was 22% (4 of 18 patients; 95% CI, 6.4%-33%) vs 13% in patients without an HRR mutation (7 of 52 patients; 95% CI, 5.6%-25.8%). ORR was 33% in patients with a BRCA mutation (1 of 3 patients; 95% CI, 0.8%-90.6%) and 6% in patients without a BRCA mutation (3 of 53 patients; 95% CI, 1.2%-15.7%). ORR was 8% in patients with an HRR mutation (1 of 12 patients; 95% CI, 0.2%-38.5%) and 3% in patients without an HRR mutation (1 of 30 patients; 95% CI, 0.1%-17.2%).

“There was high concordance between [Guardant360 or GuardantOMNI] assays and [FoundationOneCDx] for determination of BRCA (98% agreement) and HRR (87% agreement) mutational status,” the authors wrote in the study’s abstract.

“Caution should be used when interpreting these results because of small sample sizes,” they added.

Reference

Yu E, Piulats JM, Gravis G, et al. Association between homologous recombination repair mutations and response to pembrolizumab (pembro) plus olaparib (ola) in metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 Cohort A biomarker analysis. Paper presented at 2021 European Society for Medical Oncology Annual Congress; September 16-21, 2021; virtual. Abstract 73P.

Recent Videos
A third of patients had a response [to lifileucel], and of the patients who have a response, half of them were alive at the 4-year follow-up.
We are seeing that, in those patients who have relapsed/refractory melanoma with survival measured as a few weeks and no effective treatments, about a third of these patients will have a response.
We have the current CAR [T-cell therapies], which target CD19; however, we need others.
“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.
Barry Paul, MD, listed cilta-cel, anito-cel, and arlo-cel as 3 of the CAR T-cell therapies with the most promising efficacy in patients with multiple myeloma.
Jose Sandoval Sus, MD, discussed standard CAR T-cell therapies in patients across multiple high-risk lymphoma indications.
Elucidating nonresponses to bispecific T-cell engagers may be an important research consideration in the multiple myeloma field.
Barriers to access and financial toxicities are challenges that must be addressed for CAR T-cell therapies in LBCL, according to Jose Sandoval Sus, MD.
Fixed treatment durations with bispecific antibodies followed by observation may help in mitigating infection-related AEs, according to Shebli Atrash, MD.
Shebli Atrash, MD, stated that MRD should be considered carefully as an end point, given potential recurrence despite MRD negativity.
Related Content